Search Results

Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance

Authors:Jorida Çoku, University of PennsylvaniaDavid M Booth, Thomas Jefferson UnivJan Skoda, Masaryk UniversityMadison C Pedrotty, Childrens Hospital of PhiladelphiaJennifer Vogel, University of PennsylvaniaKangning Liu, Childrens Hospital of PhiladelphiaAnnette Vu, Childrens Hospital of PhiladelphiaErica L Carpenter, University of PennsylvaniaJamie C Ye, Childrens Hospital of PhiladelphiaMichelle A Chen, Childrens Hospital of PhiladelphiaPeter Dunbar, Childrens Hospital of PhiladelphiaElizabeth Scadden, Childrens Hospital of PhiladelphiaTaekyung D Yun, Columbia UniversityEiko Nakamaru-Ogiso, Childrens Hospital of PhiladelphiaEstela Area-Gomez, Columbia UniversityYimei Li, University of PennsylvaniaKelly Goldsmith, Emory UniversityPatrick C Reynolds, Texas Tech UniversityGyorgy Hajnoczky, Thomas Jefferson UniversityMichael D Hogarty, Childrens Hospital of Philadelphia

Date:2022

Publisher:WILEY

Publication Version:Final Published Version

License:Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Authors:Hongjing Zang, Emory UniversityGuoqing Qian, Emory UniversityDan Zong, Emory UniversitySongqing Fan, Central South UniversityTaofeek Owonikoko, Emory UniversitySuresh Ramalingam, Emory UniversityShi-Yong Sun, Emory University

Date:2020

Publisher:Wiley

Publication Version:Author Accepted Manuscript (After Peer Review)

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib

Authors:Zhen Chen, Emory UniversityDanlei Yu, Emory UniversityTaofeek Owonikoko, Emory UniversitySuresh Ramalingam, Emory UniversityShi-Yong Sun, Emory University

Date:2021

Publisher:SPRINGERNATURE

Publication Version:Author Accepted Manuscript (After Peer Review)

Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Authors:Hongjing Zang, Emory UniversityGuo Qian, Emory UniversityJack Arbiser, Emory UniversityTaofeek Owonikoko, Emory UniversitySuresh Ramalingam, Emory UniversitySongqing Fan, Central South UniversityShi-Yong Sun, Emory University

Date:2020

Publisher:Wiley

Publication Version:Final Published Version

License:Creative Commons Attribution 4.0 International

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Authors:Adriana E. Tron, AstraZenecaMatthew A. Belmonte, AstraZenecaAmmar Adam, AstraZenecaBrian M. Aquila, AstraZenecaLawrence Boise, Emory UniversityElisabetta Chiarparin, AstraZenecaJustin Cidado, AstraZenecaKevin J. Embrey, AstraZenecaEric Gangl, AstraZenecaFrancis D. Gibbons, AstraZenecaGareth P. Gregory, Monash UniversityDavid Hargreaves, AstraZenecaJ. Adam Hendricks, AstraZenecaJeffrey W. Johannes, AstraZenecaRicky W. Johnstone, Peter MacCallum Cancer CenterSteven L. Kazmirski, Fulcrum TherapeuticsJason G. Kettle, AstraZenecaMichelle L. Lamb, AstraZenecaShannon Matulis, Emory UniversityAjay Nooka, Emory UniversityMartin J. Packer, Emory UniversityBo Peng, AstraZenecaPhilip B. Rawlins, AstraZenecaDaniel W. Robbins, AstraZenecaAlwin G. Schuller, AstraZenecaNancy Su, AstraZenecaWenzhan Yang, AstraZenecaQing Ye, AstraZenecaXiaolan Zheng, AstraZenecaJ. Paul Secrist, AstraZenecaEdwin A. Clark, AstraZenecaDavid M. Wilson, AstraZenecaStephen E. Fawell, AstraZenecaAlexander W. Hird, AstraZeneca

Date:2018

Publisher:Nature Research (part of Springer Nature): Fully open access journals

Publication Version:Final Published Version

License:Creative Commons Attribution 4.0 International

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Authors:Shannon Matulis, Emory UniversityVikas Gupta, Emory UniversityAjay Nooka, Emory UniversityHayley Von Hollen, Emory UniversityJonathan Kaufman, Emory UniversitySagar Lonial, Emory UniversityLawrence Boise, Emory University

Date:2016

Publisher:Nature Publishing Group

Publication Version:Author Accepted Manuscript (After Peer Review)

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia

Authors:Brian T. Gaudette, Emory UniversityBhakti Dwivedi, Emory UniversityKasyapa Chitta, Mayo ClinicStéphanie Poulain, Hopital de ValenciennesDoris Powell, Emory UniversityPaula Vertino, Emory UniversityXavier Leleu, CHRU LilleSagar Lonial, Emory UniversityAsher A. Chanan-Khan, Mayo ClinicJeanne Kowalski, Emory UniversityLawrence Boise, Emory University

Date:2016

Publisher:Nature Publishing Group

Publication Version:Author Accepted Manuscript (After Peer Review)

Search

Search Constraints

Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib

Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax

Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia

Limit your search

Authors

Date

Journal or Parent Publication Title

Type

Publication Version

Keyword